<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">93665</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Antigistaminnye preparaty: sovremennye kriterii vybora</article-title><trans-title-group xml:lang="ru"><trans-title>Антигистаминные препараты: современные критерии выбора</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fomina</surname><given-names>D. S</given-names></name><name xml:lang="ru"><surname>Фомина</surname><given-names>Д. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Drobik</surname><given-names>O. S</given-names></name><name xml:lang="ru"><surname>Дробик</surname><given-names>О. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Goryachkina</surname><given-names>L. A</given-names></name><name xml:lang="ru"><surname>Горячкина</surname><given-names>Л. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГБОУ ДПО Российская медицинская академия последипломного образования, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2012-11-15" publication-format="electronic"><day>15</day><month>11</month><year>2012</year></pub-date><volume>14</volume><issue>11</issue><issue-title xml:lang="en">VOL 14, NO11 (2012)</issue-title><issue-title xml:lang="ru">ТОМ 14, №11 (2012)</issue-title><fpage>11</fpage><lpage>16</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/93665">https://consilium.orscience.ru/2075-1753/article/view/93665</self-uri><abstract xml:lang="ru"><p>История антигистаминных препаратов (АГП) насчитывает не одно десятилетие, но антагонисты Н1-рецепторов были и остаются важнейшими инаиболее широко применяемыми в широкой клинической практике медикаментами. Несмотря на длительный опыт и широкое использование АГП постоянно возникает ряд дискуссионных положений, касающихся их применения. Это возобновляет интерес к данной группе лекарственных средств (ЛС). Безусловно, антигистаминные средства (АГС) различны по механизмам действия, каждый из них имеет свои преимущества и недостатки, а выбор врачом наиболее подходящего препарата для пациента определяется конкретной клинической ситуацией, его знаниями характеристики препарата и опытом применения. Между тем современный клинический взгляд сосредоточен на аспектах безопасности применения АГП и обоснованного выборалекарств с позиции доказательной медицины. В поиске профиля безопасности анализируются данные научных изысканий, многолетний клинический опыт применения, результаты международных клинических исследований</p></abstract></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Горячкина Л.А., Передкова Е.В. Антигистаминные препараты. 2004.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус Принт, 1998.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ненашева Н. Астма и аллергия. Врач. 2008; 11: 15–9.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Саймонс Э. Отчет о докладе: Антигистаминные препараты. Не навреди. Практика педиатра. От исследований к практике. 2009; с. 20–2.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Томилова А.Ю., Намазова Л.С, Кузенкова Л.Н., Маслова О.И. Коррекция нарушений когнитивной сферы у детей с аллергическим ринитом. Вопросы современной педиатрии. 2007; 2: 123–7.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Agrawal et al. Allergy 2000; 55: 276.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Agrawal. Clin Exp Allergy 2004; 34: 1342.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bousquet J et al. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 2003; 58: 192.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bousquet J, Bindslev-Jensen C, Canonica G.W. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy 2004; 59 (Suppl. 77): 4–16.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Bousquet J, Khaltaev N, Cruz A et al. Allergic rhinitis and its impact on asthma (ARIA). Allergy 2008; 63 (Suppl. 86): 9–160</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Boyle J, Erilesson M et al. Allergy medication in Japanese volunteers: treatment effect of single doses on natural sleep architecture and next day residual effects. Curr Med Res Opin 2006; 22: 1343–51.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Church M, Maurer M, Simons F et al. Risk of first – generation H1 - antihistamines: a GA2LEN position paper. Allergy 2010; 65: 459–66.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Cockburn M, Bailit H et al. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999; 41: 948–53.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Daly A. Allergy 2001; 56 (Suppl. 68): 79.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Garoia-Gea C, Martinez-Colomer J et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of histamine, a new H1 antihistamine a dose - range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008; 28: 675–85.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Genovese et al. Clin Exp Allergy 1997; 27: 559.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Golightly L, Greos L. Second - generation antihistamines: actions efficacy in the management of allergic disorders. Drugs 2005; 65 (3): 341–84.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Juniper E.F., Stahl E, Doty R, Simons E.F. Clinical outcomes and adverse effect monitoringin allergic rhinitis J Allergy Clin Immunol 2005; 3(Suppl. 1): 390–413.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kay G, Berman B et al. Initial and steady - effects of diphenhydramine and loratadine on sedation, cognition, mood and psychomotor performance. Arch Intern Med 1997; 157: 2350–6.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kleine-Tebbe et al. J Allergy Clin Immunol 1994; 93: 494.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kreutner et al. Arzneimittelforschung 2000; 50: 345.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Leurs R, Church M.K., Taglialatela M. H1 - antihistamines: inverse agonism, anti - inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489–98.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Lippert et al. Exp Dermatol 1995; 4: 272.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Mc Donagh M et al. Drug Class Review: Newer Antihistamines. Final Report Update 2010; 1–72.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Molet et al. Clin Exp Allergy 1997; 27 (1167): 34.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Nine J.S., Rund C.R. Fatality from diphenhydramine monointoxication: a case report and review of the infant, pediatric, and adultliterature. Am J Forensic Med Pathol 2006; 27: 36–41.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Paton D, Webster D et al. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet 1985; 10: 477–97.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Richurdson G, Roehrs T. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002; 22: 511–5.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Ring J. Int J Dermatol 2001.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Shamsi Z, Hindmarch T. Sedation and antihistamines: a review of inter - drug differences using proportional impairment rations. Hum Psychopharmocol 2000; 15: 3–30.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Schroder et al. Clin Exp Allergy 2001; 31: 1369.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Simons E.F. et al. Advanced in H1 - antihistamines. N Engl J Med 2004; 351: 2203–17.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Strenkoski-Nix L.C., Ermer J et al. Pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects. Am J Health Syst Pharm 2000; 57: 1499–500.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Source: Summaries of Product Characteristics, Avaiable at: http://emc.medicines.org.uk</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Tashiro M et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepness, and brain histamine H1-receptor Occupancy Using C-Doxepin Positron Emission Tomography. J Clin Pharmacol 2004; 44: 890–900.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Tashiro M, Mochizuki H, Iwabuchi K et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1-receptors in human brain. Life Sci 2002; 72 (4–5): 40–14. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1-receptors in human brain.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Vignola et al. Allergy 1995; 50: 200.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Weiler J, Bloomfiekl J et al. Effectsof fexofenadine, difenhydramine and alcohol on driving performance. A randomized, placebo - controlled trial in the Lowa driving simulator. Ann Inter Med 2000; 132: 354–63.</mixed-citation></ref></ref-list></back></article>
